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Abstract
Background: Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients
with aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD). The objective of
this study was to describe optic neuritis (ON)-induced neuro-axonal damage in the retina of MOG-IgG-positive
patients in comparison with AQP4-IgG-positive NMOSD patients.
Methods: Afferent visual system damage following ON was bilaterally assessed in 16 MOG-IgG-positive patients
with a history of ON and compared with that in 16 AQP4-IgG-positive NMOSD patients. In addition, 16 healthy
controls matched for age, sex, and disease duration were analyzed. Study data included ON history, retinal optical
coherence tomography, visual acuity, and visual evoked potentials.
Results: Eight MOG-IgG-positive patients had a previous diagnosis of AQP4-IgG-negative NMOSD with ON and
myelitis, and eight of (mainly recurrent) ON. Twenty-nine of the 32 eyes of the MOG-IgG-positive patients had
been affected by at least one episode of ON. Peripapillary retinal nerve fiber layer thickness (pRNFL) and ganglion
cell and inner plexiform layer volume (GCIP) were significantly reduced in ON eyes of MOG-IgG-positive patients
(pRNFL = 59 ± 23 μm; GCIP = 1.50 ± 0.34 mm3) compared with healthy controls (pRNFL = 99 ± 6 μm, p < 0.001; GCIP
= 1.97 ± 0.11 mm3, p < 0.001). Visual acuity was impaired in eyes after ON in MOG-IgG-positive patients (0.35 ± 0.88
logMAR). There were no significant differences in any structural or functional visual parameters between MOG-IgG-
positive and AQP4-IgG-positive patients (pRNFL: 59 ± 21 μm; GCIP: 1.41 ± 0.27 mm3; Visual acuity = 0.72 ± 1.09
logMAR). Importantly, MOG-IgG-positive patients had a significantly higher annual ON relapse rate than AQP4-IgG-
positive patients (median 0.69 vs. 0.29 attacks/year, p = 0.004), meaning that on average a single ON episode
caused less damage in MOG-IgG-positive than in AQP4-IgG-positive patients. pRNFL and GCIP loss correlated with
the number of ON episodes in MOG-IgG-positive patients (p < 0.001), but not in AQP4-IgG-positive patients.
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Conclusions: Retinal neuro-axonal damage and visual impairment after ON in MOG-IgG-positive patients are as
severe as in AQP4-IgG-positive NMOSD patients. In MOG-IgG-positive patients, damage accrual may be driven by
higher relapse rates, whereas AQP4-IgG-positive patients showed fewer but more severe episodes of ON. Given the
marked damage in some of our MOG-IgG-positive patients, early diagnosis and timely initiation and close
monitoring of immunosuppressive therapy are important.
Keywords: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG), aquaporin-4 antibodies (AQP4-IgG), NMO-
IgG, neuromyelitis optica, Devic syndrome, neuromyelitis optica spectrum disorders (NMOSD), optic neuritis, optical
coherence tomography, visual evoked potentials, visual acuity, retinal neuro-axonal damage
Background
Myelin oligodendrocyte glycoprotein (MOG) is expressed
on the outer surface of oligodendrocytic myelin sheaths,
representing approximately 0.05 % of all myelin-
constituting proteins [1]. Antibodies against MOG
(MOG-IgG) have been detected in a proportion of
aquaporin-4 (AQP4)-IgG-seronegative patients with
neuromyelitis optica spectrum disorder (NMOSD) pheno-
type [2–6]. MOG-IgG have further been reported in chil-
dren with acute and relapsing-remitting inflammatory
demyelinating encephalomyelitis as well as in a proportion
of adults with inflammatory demyelinating diseases such
as optic neuritis (ON) [7–9].
Currently it is debated whether MOG-IgG-associated
encephalomyelitis should be classified as an NMOSD
subtype or as a separate disease entity [10–12]. MOG-
IgG-seropositive patients from NMOSD cohorts can
show clinical features of recurrent transverse myelitis
and ON, similar to AQP4-IgG-seropositive patients [4].
However, the cellular target of AQP4-IgG is an astro-
cytic water channel, suggesting a different mechanism of
injury from MOG-IgG. This is supported by a recent
case study of a MOG-IgG-seropositive patient who
showed severe demyelination with no evidence of astro-
cytopathy [13] and by further brain biopsy case studies
[14–16].
ON in NMOSD patients is often severe with marked
retinal nerve fiber layer and ganglion cell layer loss, se-
vere visual impairment including blindness, and a high
frequency of bilateral events [17, 18]. In around 20 % of
affected eyes, macular microcysts are found in the inner
nuclear layer as a sign of severe ON-related retinal in-
jury [19, 20]. In comparison, the extent of afferent visual
system damage following ON in MOG-IgG-seropositive
patients is less well understood.
Some previous studies, employing either structural or
clinical assessment of visual function, suggested that
MOG-IgG-positive patients have fewer attacks, better
recovery from relapses, and less neuro-axonal retinal
damage than AQP4-IgG-positive patients [4, 21, 22].
However, it is a potential drawback that observation pe-
riods were relatively short and sample sizes low in those
studies. Moreover, some included mostly or exclusively
Asian patients [4, 22]; this could be relevant in that gen-
etic factors have been proposed to play a role in
NMOSD pathogenesis [17]. By contrast, more recent
studies by others [23, 24] and us [25] demonstrate that
the disease follows a relapsing course in the long run in
most MOG-IgG-positive patients.
The objective of this retrospective multicenter study
was to investigate visual system damage after ON in a
larger cohort of Caucasian patients with MOG-IgG-
associated encephalomyelitis and long-term follow-up
using a comprehensive assessment of the afferent visual
system including structural, functional, and clinical pa-
rameters, and to compare it with that in AQP4-IgG-
positive NMOSD patients.
Methods
Patients
MOG-IgG-seropositive patients with a history of ON
and available optical coherence tomography (OCT) data
were recruited from a large retrospective study [25, 26].
Sixteen patients (15 female; mean age 44.0 ± 15.2 years)
were enrolled from six university hospitals in Europe
(Germany: Berlin, Freiburg, Düsseldorf, Heidelberg,
Würzburg; Denmark: Vejle). The inclusion criteria were
age ≥18 years, a confirmed history of ON (more than
3 months prior to visual assessments), and seropositivity
for MOG-IgG. A MOG-antibody serum titer of ≥1: 160
was classified as positive [26]. Clinical and paraclinical
data on disease onset, relapse history, expanded disabil-
ity status scale (EDSS) [27], visual acuity, OCT, magnetic
resonance imaging (MRI), and immunotherapy were
retrospectively collected.. Annualized relapse rate was
calculated as the ratio of number of attacks and years
since disease onset, excluding patients with disease dur-
ation of less than 1 year. All patients were of Caucasian
descent; all MOG-IgG-positive patients tested seronega-
tive for AQP4-IgG, and vice versa (Table 1). Eight (50 %)
MOG-IgG-positive patients had a previous diagnosis
of—mainly recurrent—ON, and eight (50 %) had been
diagnosed with NMOSD based on the clinical symptoms
of ON and myelitis before anti-MOG-IgG was tested.
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AQP4-IgG-positive NMOSD patients [28] (n = 16, all
female, mean age 43.2 ± 13.9 years) and healthy con-
trols (HC, n = 16, 15 female, mean age 43.9 ± 15.4 years)
were randomly selected from the research database of
the NeuroCure Clinical Research Center (Charité –
Universitätsmedizin Berlin, Berlin, Germany), matched
for sex and age on cohort basis. Two MOG-IgG-
positive patients had co-occurring ophthalmologic
conditions in both eyes: one had early-stage dry macu-
lar degeneration, and glaucoma was suspected in the
other patient. These two patients and their matched
AQP4-IgG-positive patients and HC were included in
the case descriptions but excluded from statistical analyses
of OCT and visual function parameters. Furthermore, only
eyes with a previous ON were included in statistical ana-
lyses. The local ethics committees approved the study
protocol in accordance with the Declaration of Helsinki
(1964) in its currently applicable version. All participants
provided informed written consent.
MOG-IgG and AQP4-IgG assay
MOG-IgG antibodies were detected using a live cell-
based assay and a fixed cell-based assay, both employing
HEK293 cells transfected with human full-length MOG;
mock-transfected cells were used as control substrates (see
part 1 for details [26]). AQP4-IgG were detected using a
commercially available cell-based assay (EUROIMMUN,
Lübeck, Germany) [29, 30].
Optical coherence tomography
OCT was performed using the Spectralis SD-OCT de-
vice (Heidelberg Engineering, Heidelberg, Germany) with
the automatic real time function for image averaging.
Peripapillary retinal nerve fiber layer thickness (pRNFL)
was derived from a standard ring scan around the optic
nerve head (12°, 768 or 1536 A-scans, 16≤ART≤100). A
macular volume scan (25° × 30°, 61 vertical or horizontal
B-scans, 768 A-scans per B-scan, 9≤ART≤15) was ac-
quired for retinal layer analysis. All scans underwent qual-
ity control [31] and post-processing by one experienced
rater in a standardized manner. Layer segmentation was
performed with the device’s software (Eye Explorer
1.9.10.0 with viewing module 6.0.9.0). Automatic segmen-
tation results were carefully checked for errors and cor-
rected if necessary by an experienced rater masked for the
diagnosis of the subjects. Combined ganglion cell and
inner plexiform layer volume (GCIP), inner nuclear layer
volume, and outer retinal layers volume including the
outer plexiform and nuclear layer, inner and outer photo-
receptor segments, and retinal pigment epithelium, were
extracted from a 6-mm-diameter cylinder around the
fovea [32]. Furthermore, all scans were examined for
macular microcysts [19] and other retinal pathologies.
The OCT parameters are visualized in Fig. 1.
Visual function testing
Visual function testing was performed in MOG-IgG-
positive and AQP4-IgG-positive patients at the same
visit as OCT, except for one patient (see Additional file
1: Table S1). Visual evoked potentials (VEP) were re-
corded with checkerboard stimulation (1°) with the
device routinely used at the sites. P100 peak latency was
included in analysis and considered as abnormal when
higher than 112 ms [33] or when no clear signal could
be evoked. Habitually corrected visual acuity was tested
with letter charts obtained as part of routine clinical care
Table 1 Demographic data
MOG-IgG AQP4-IgG MOG-IgG vs. AQP4-IgG (MWU/Chi2)
p
Patients N 16 16
Age (years) Mean ± SD 44.0 ± 15.2 43.2 ± 13.9 0.838
Sex (f/m) 15/1 16/0 >0.999
Ophthalmologic comorbidities N 2a) (13 %) 0 (0 %)
Age at onset (years) Mean ± SD 37.2 ± 15.1 34.7 ± 14.8 0.669
Time since onset (years) Mean ± SD 6.9 ± 6.5 8.4 ± 6.8 0.287
ON eyes N (%) 29 (91.6 %) 25 (78.1 %)
Number of ON episodes Median (range) 4.5 (1–13) 2 (1-4) 0.012
Myelitis prevalence N (%) 8 (50 %) 15 (93.8 %) 0.018
ARR Median (range) 1.25 (0.38–7.14) 0.64 (0.17–1.44) 0.026
ON ARR Median (range) 0.69 (0.17–7.14) 0.29 (0.07–0.96) 0.004
EDSS Median (range) 3.0 (1.0–7.5) 4.0 (1.0–6.5) 0.064
Abbreviations: AQP4-IgG aquaporin-4 antibody-seropositive NMOSD patients, ARR annualized relapse rate, EDSS expanded disability status scale, f female, m male,
MOG-IgG myelin oligodendrocyte glycoprotein antibody-seropositive patients, MWU Wilcoxon-Mann-Whitney U test, ON optic neuritis, SD standard deviation
a)Early stage dry macular degeneration in both eyes and suspect for early stage glaucoma, respectively
p-values in bold emphasis depict significant values (p < 0.05)
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and converted into logMAR units. A visual acuity of 0.2
logMAR and worse was considered abnormal. When no
letter could be recognized by the patient, visual acuity
was registered with 2.0 logMAR for finger counting and
3.0 logMAR for hand motion recognition [34].
Data analysis
Statistics were performed in R version 3.1.2 [35] using
the packages psych, MASS, geepack and ggplot. Differ-
ences in demographics between the cohorts were tested
with Pearson chi-square test and non-parametric tests
(Mann-Whitney U for two cohorts and Kruskal-Wallis
for three cohorts). Comparisons of visual system data
between cohorts were performed using generalized
estimating equation (GEE) models accounting for intra-
subject inter-eye dependencies. GEE results are provided
with regression coefficient (B) and standard error (SE).
To investigate the extent of damage caused by subse-
quent ON episodes we employed a linear spline regres-
sion model as proposed by Ratchford et al. [36]. Due to
the exploratory nature of this study, no correction for
multiple comparisons was performed.
Results
The demographic and clinical features of MOG-IgG-
positive patients are presented in Table 1 and case-by-
case clinical details are provided in Additional file 1:
Table S1. One patient had pediatric onset of the disease,
Fig. 1 Sample images from patient 1. a Sample images from a peripapillary ring scan. On the left, a scanning laser ophthalmoscopy image shows scan
positioning (in green). On the right, an OCT scan shows severe peripapillary retinal nerve fiber layer (pRNFL) loss (between the inner limiting membrane
[ILM], shown in red, and the lower border, in turquoise). b Ring-scan data in comparison with normative device data from both eyes of this patient.
Black numbers display the thickness measurements (in μm) of the subject, green numbers the average thickness in the age-matched reference group.
Sectors are classified in comparison with the reference group: green, thickness values within the 5th and 95th percentile range; yellow, 1st to 5th
percentile range; red, below the 1st percentile. Abbreviations: G global, NS nasal-superior, N nasal, NI nasal-inferior, TI temporal-inferior, T temporal, TS
temporal-superior. c Macular scan of the same patient. On the left, the dark, sickle-shaped area on and around the macula represents tissue with
microcysts in the inner nuclear layer (INL). The white circle indicates the 6-mm-diameter cylinder in which intraretinal layers are analyzed. The green line
with arrow shows the scanning position of the OCT scan on the right. Here, the defined layers are the RNFL, the ganglion cell and inner plexiform layer
(GCIP), then INL and the outer retinal layers (ORL). Macular microcysts can be seen as small black dots in the INL
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at 6 years of age; her case has been reported in an earlier
publication [11]. All other patients had adult onset. All
MOG-IgG-positive patients had experienced at least one
episode of ON (median 4.5, range 1–13) and, except for
one with a short follow-up period (8 months, patient 8),
presented with an unequivocally relapsing disease
course. Age at onset and disease duration at the time of
examination did not differ between MOG-IgG-positive
and AQP4-IgG-positive patients (Table 1). Detailed case
studies, including therapy, are provided in parts 2 and 3
of this series of articles [25, 37].
OCT and visual function in MOG-IgG-positive ON
Two eyes from two patients had to be excluded from the
analysis owing to acute ON at the time of assessment.
Thus, 23 eyes from 14 MOG-IgG-positive patients were
analyzed at a median time of 16.4 months (range 3–125
months) since the most recent episode of ON. Detailed
afferent visual system parameters of all patients are given
in Table 2, and case-by-case descriptions are provided in
Additional file 2: Table S2.
Reduced pRNFL thickness compared with the manu-
facturer’s normative data was found in 18 of the 23
(78.2 %) ON-affected eyes of the MOG-IgG-positive
group (mean 59 ± 23 μm). In addition, two fellow eyes
without clinically evident previous ON and with normal
VEPs showed reduced RNFL thickness (51 μm and
75 μm, respectively). Five ON eyes (21.7 %) but none of
the non-ON eyes had macular microcysts in the inner
nuclear layer. Of 20 ON eyes with available VEP data, 12
(60 %) eyes had abnormal P100 latencies—two (10 %) of
them despite normal pRNFL—while all four non-ON
fellow eyes had normal VEPs. Visual acuity was on aver-
age reduced in ON eyes (mean 0.35 ± 0.88 logMAR),
with three eyes being legally blind at a visual acuity of 1.0
logMAR and worse. On the other hand, 16 of 23 ON eyes
(70 %) preserved visual acuity of 0.1 logMAR or better.
There were no significant differences in OCT and visual
function measurements between MOG-IgG-positive pa-
tients with a history of both ON and myelitis (n = 8)
and MOG-IgG-positive patients with a history only of
recurrent ON (n = 8) (not shown).
Comparison with HC and AQP4-IgG-positive NMOSD
patients
We then compared the afferent visual system damage in
ON eyes of MOG-IgG-positive patients with age- and
sex-matched HC and with ON eyes of AQP4-IgG-
positive NMOSD patients (Table 2, Fig. 2). As expected,
pRNFL and GCIP were significantly lower than in HC
both in the MOG-IgG-positive group (both p < 0.001)
and in the AQP4-IgG-positive group (both p < 0.001).
Furthermore, inner nuclear layer volume was signifi-
cantly greater than HC in the MOG-IgG-positive sub-
group (p = 0.009), but not in the AQP4-IgG-positive
NMOSD subgroup. By contrast, no significant difference
was noted between MOG-IgG-positive and AQP4-IgG-
positive patients regarding retinal layer measures. Macular
Table 2 Structural and functional data of MOG-IgG-positive patients’ ON eyes in comparison to AQP4-IgG-positive patients
and control data
MOG-IgG positive ON
(n = 23 eyes from
14 subjects)
AQP4-IgG positive ON
(n = 21 eyes from
14 subjects)
HC (n = 28 eyes from
14 subjects)
MOG-IgG positive vs.
AQP4-IgG positive (GEE)
MOG-IgG positive
vs. HC (GEE)
B SE p B SE p
Retinal OCT
Average pRNFL (μm) 59 ± 23 59 ± 21 99 ± 6 −0.6 7.58 0.94 39.0 6.01 <0.001
Nasal pRNFL (μm) 44 ± 21 45 ± 24 74 ± 12 0.2 7.85 0.98 28.6 6.01 <0.001
Temporal pRNFL (μm) 44 ± 16 40 ± 15 71 ± 10 −3.0 4.51 0.50 27.6 4.26 <0.001
GCIP (mm3) 1.50 ± 0.34 1.41 ± 0.27 1.97 ± 0.11 −0.10 0.10 0.35 0.47 0.08 <0.001
INL (mm3) 1.03 ± 0.10 1.01 ± 0.11 0.95 ± 0.04 −0.02 0.04 0.55 −0.07 0.03 0.009
ORL (mm3) 4.86 ± 0.26 4.93 ± 0.26 4.73 ± 0.21 0.04 0.09 0.70 −0.13 0.09 0.14
Eyes with macular
microcysts (n)
5 (21.7 %) 4 (19.0 %) Chi2 >0.99
Visual function
Visual acuity/logMAR 0.35 ± 0.88 0.72 ± 1.09 - 0.33 0.32 0.30
Abnormal P100 latency* 12 (57 %) 10 (50 %) - Chi2 0.88
OCT and visual function results are not including data from the two patients with early stage dry macular degeneration in both eyes and glaucoma, respectively, and
their respective AQP4-IgG-positive controls and healthy controls. Furthermore, two eyes of two MOG-IgG positive patients were excluded due to acute ON at time of
examination. Explanations: All data are given as mean ± standard deviation (minimum – maximum), if not declared different
AQP4-IgG aquaporin-4 antibody-seropositive NMOSD patients, GCIP ganglion cell and inner plexiform layer, HC healthy controls, INL inner nuclear layer, ON eyes
with history of optic neuritis, MOG-IgG myelin oligodendrocyte glycoprotein antibody-seropositive patients, ORL outer retinal layers including layer from outer
plexiform layer to Bruch’s membrane, pRNFL peripapillary retinal nerve fiber layer
p-values in bold emphasis depict significant values (p < 0.05)
* VEP data were available for 20 out of 23 ON eyes of MOG-IgG positive patients and 20 out of 21 eyes of AQP4-IgG positive patients
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microcysts were found in both subgroups in similar preva-
lence, but differences in microcyst size or extend might
have led to a high variability of inner nuclear layer volume
values (Table 2). Visual acuity was less impaired in the
MOG-IgG-positive subgroup (mean 0.35 ± 0.88 logMAR)
than in the AQP4-IgG-positive subgroup (0.72 ± 1.09);
however, the difference was not significant (p = 0.30).
Of note, the MOG-IgG-positive patients showed a
significantly higher annualized relapse rate both for all
relapses and—even higher—for ON than the AQP4-IgG-
positive patients (p = 0.026 and p = 0.004, respectively),
despite similar disease duration (Table 1).
Retinal damage and number of ON episodes
In MOG-IgG-positive patients, a higher number of ON epi-
sodes was associated with more severe pRNFL and GCIP
loss (GEE: pRNFL B = −4.9, SE = 1.40, p < 0.001; GCIP B =
−0.07, SE = 0.02, p < 0.001), but not with changes of the
inner nuclear layer or outer retinal layers. By contrast, in
AQP4-IgG-positive patients the extent of retinal layer
changes did not correlate with the number of ON attacks.
In our cross-sectional data, the first ON episode
caused a mean pRNFL loss of 12.8 μm (p = 0.001) in
MOG-IgG-positive patients and 32.8 μm (p < 0.001) in
AQP4-IgG-positive patients in comparison with HC
eyes. In contrast, a second episode of ON caused add-
itional pRNFL loss of 37.8 μm (p < 0.001) in MOG-IgG-
positive patients and 20.8 μm in AQP4-IgG-positive pa-
tients, although that difference was not significant (p =
0.07) (Fig. 3). A similar association was found for GCIP
volume (data not shown).
Discussion
This study shows that ON in MOG-IgG-positive patients
leads to severe pRNFL and GCIP thinning and visual
function impairment, the extent of which is comparable
to ON in patients with AQP4-IgG. Moreover, it suggests
that the damage accrual may be driven by higher relapse
rates in MOG-IgG-positive patients, in contrast to more
severe ON-associated damage during a single ON epi-
sode in AQP4-IgG-positive patients.
Some earlier studies of MOG-IgG-positive patients,
which were characterized by relatively short observation
Fig. 2 Retinal layer measures of MOG-IgG-positive and AQP4-IgG-positive ON eyes. Boxplots for the comparison of retinal layer measures of the
eyes in the healthy control group and the ON eyes of MOG-IgG-positive (MOG-IgG+) and AQP4-IgG-positive (AQP4-IgG+) NMOSD patients. (a)
Peripapillary retinal nerve fiber layer thickness derived from a ring scan (pRNFL); (b-d) Intraretinal layer volumes quantified in a 6-mm-diameter
cylinder around the fovea centralis: (b) ganglion cell and inner plexifom layer volume (GCIP); (c) inner nuclear layer volume (INL); (d) outer retinal
layer volume comprising all layers from outer plexiform layer to Bruch’s membrane
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periods, suggested that MOG-IgG-seropositive patients
present more often with monophasic disease and have a
milder clinical phenotype and better recovery than patients
with AQP4-IgG-seropositive NMOSD [4, 5, 38]. By con-
trast, all but one of our patients showed a relapsing disease
course with a high frequency of attacks, protracted ON ep-
isodes, and, in some cases, severe visual impairment. In
line with our findings, two more recent studies have also
demonstrated that MOG-IgG seropositivity is frequently
associated with a recurrent disease course in patients with
ON [23, 24]. Concerning neuro-axonal damage of the ret-
ina, a recent study including 19 MOG-IgG-positive pa-
tients reported less retinal nerve fiber and ganglion cell
layer damage than in AQP4-IgG-positive patients following
ON [22]. As a limitation, however, that study included ex-
clusively monophasic patients. By contrast, in our study we
demonstrated that retinal neuro-axonal damage after ON
in MOG-IgG-positive patients is at least as severe as in
AQP4-IgG-positive NMOSD patients, compared with our
own control cohort as well as with previously published
AQP4-IgG-positive cohorts [39, 40] when patients with
long-term follow-up (mean ~7 years) and, accordingly, re-
lapsing disease course are included in the analysis.
Notably, although average visual function was impaired
in relapsing ON of both MOG-IgG-positive and AQP4-
IgG-positive patients, some MOG-IgG-positive patients
performed comparably well on high-contrast visual acuity
testing despite severe neuro-axonal retinal damage: 70 %
of ON eyes retained a visual acuity of 0.1 logMAR or
better after ON. However, visual acuity was obtained in
non-standardized manner as high-contrast letter acuity in
clinical routine; thus the reliance on functional testing
may underestimate the actual extent of damage to the
afferent visual system. The impact of structural damage as
demonstrated in the present study should be further
investigated with low-contrast letter acuity, color vision
testing, visual fields, and quality of life scales.
Our study features strengths and limitations. Among
its strengths we count the relatively high number of
patients included, given the low prevalence of the dis-
ease, the fact that reliable assays for detecting antibodies
to full-length human MOG have become available only
relatively recently, and the fact that OCT is not yet rou-
tinely and generally available. A further potential strength
is that our cohort was genetically homogeneous with all
patients and controls being of Caucasian origin. As a po-
tential limitation, not all patients were systematically
tested for other optic neuropathies, such as Leber’s heredi-
tary optic neuropathy (LHON). While a mitochondrial
mutation may have contributed to the marked pRNFL
thinning in the female patient with pediatric onset of dis-
ease (patient 4 in Additional file 1: Table S1), the time
course (approximately 10 years before the contralateral
eye demonstrated a mild decrease in visual acuity) is un-
usual for LHON, a condition which typically affects both
eyes within months of each other without a relapsing and
remitting course. Finally, data were collected retrospect-
ively in a multicenter approach. As a result, additional
data, e.g., the Multiple Sclerosis Function Composite or
OCT scans obtained during acute optic neuritis, were not
available. Moreover, we were not able to systematically
correlate optic nerve MRI [23, 41] and OCT in this study,
Fig. 3 Retinal nerve fiber layer loss as a function of optic neuritis in MOG-IgG-positive and AQP4-IgG-positive patients. Peripapillary retinal nerve
fiber layer (pRNFL) loss caused by sequential episodes of optic neuritis (ON), estimated from cross-sectional data, in comparison with eyes without
optic neuritis from the healthy control (HC) cohort. (a) ON eyes from MOG-IgG-seropositive patients (MOG-IgG+); (b) ON eyes from AQP4-IgG-
seropositive patients (AQP4-IgG+). P-values were computed with linear regressions
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which would require highly standardized MRI protocols
and a prospective study design. However, prospective
studies as well as single-center studies in MOG-IgG-
positive patients are difficult to perform due to the condi-
tion’s rarity and the currently limited access to MOG-IgG
testing. Moreover, all patients with available data seen at
the various centers were included in the analysis, thereby
reducing the risk of referral bias. Nonetheless, the prelim-
inary evidence derived from this retrospective exploratory
study needs to be confirmed in further prospective and
independent studies.
Conclusions
In summary, we demonstrate (a) that a substantial propor-
tion of MOG-IgG-seropositive patients develop retinal
neuro-axonal damage; (b) that visual impairment and
structural damage increase with the number of attacks
and thus with disease duration; and, importantly, (c) that
the extent of neuro-axonal damage in MOG-IgG-positive
patients with ON is not different from that in patients
with AQP4-IgG-positive ON in the long-term course of
the disease, i.e., when patients with relapsing rather than
monophasic ON are taken into account. Given the
marked structural and functional damage in some of our
ON patients, early diagnosis, timely initiation of immuno-
suppressive therapy, and close monitoring of treatment
efficacy seem paramount. Although no systematic investi-
gations of drugs for relapse prevention in this condition
have yet been conducted, retrospective data on treatment
responses (see part 2 of this series [25]), as well as avail-
able evidence in favor of a pathogenic role of MOG-IgG
[16, 30], suggest that—in accordance with treatment rec-
ommendations for AQP4-IgG-positive NMOSD [42]—pa-
tients with MOG-IgG-positive ON may benefit from
high-dose intravenous methylprednisolone treatment and,
possibly, plasma exchange for acute attacks as well as
from immunosuppression for attack prevention.
Additional files
Additional file 1: Table S1. Demographic, clinical and serological data.
a) Early stage dry macular degeneration in both eyes; b) Suspected early
stage glaucoma. c) Visual assessments were performed during acute ON OS.
Abbreviations: ON: optic neuritis. VEP P100: visually evoked potential P100
latency. n.e.: not evocable; pRNFL: peripapillary retinal nerve fiber layer
thickness. GCIP: combined ganglion cell and inner plexiform layer volume.
INL: inner nuclear layer volume. ORL: outer retinal layers volume including
layers from outer plexiform layer to Bruch’s membrane. (DOCX 21 kb)
Additional file 2: Table S2. Visual evoked potentials, visual acuity, and
OCT results. a) Protracted relapses were registered as one episode; b) Early
stage dry macular degeneration in both eyes; c) Suspected early stage
glaucoma; d) Medication other than acute relapse therapy
(immunotherapy). Abbreviations: AQP4-IgG = aquaporin-4 antibodies;
CRION = chronic relapsing inflammatory optic neuropathy; EDSS = ex-
panded disability status scale; F = female; MOG-IgG =myelin
oligodendrocyte glycoprotein antibodies; NMOSD = neuromyelitis optica
spectrum disorders; (r)ON = (recurrent) optic neuritis. (DOC 59 kb)
Abbreviations
AQP4-IgG: Aquaporin-4 immunoglobulin G; ARR: Annualized relapse rate;
EDSS: Expanded disability status scale; GCIP: Ganglion cell and inner
plexiform layer volume; GEE: Generalized estimating equation; LHON: Leber’s
hereditary optic neuropathy; MOG-IgG: Myelin oligodendrocyte glycoprotein
antibody-seropositive patients; MWU: Wilcoxon-Mann-Whitney U test;
OCT: Optical coherence tomography; ON: Optic neuritis; pRNFL: Peripapillary
retinal nerve fiber layer thickness; SD: Standard deviation; SE: Standard error;
VEP: Visual evoked potentials
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